Porda Havas assisted the first medical AI company Airdoc Technology (2251.HK) to be successfully listed on the main board of the Hong Kong Stock Exchange
Latest Update:
5 th November, 2021

On November 5, 2021, Beijing Airdoc Technology Development Co., Ltd. ("Airdoc Technology" or the "Company", stock code: 2251.HK), a leading artificial intelligence medical device company in China, listed on the Hong Kong Stock Exchange today. Limited ("Stock Exchange") listed on the main board, becoming the first medical AI stock.

Airdoc Technology’s global offering of 22,267,200 H shares at an issue price of HK$75.1 per share, after deducting the underwriting fees, commissions and estimated expenses payable for the global offering, and assuming that the over-allotment option has not been exercised, the net proceeds from the global offering It is expected to be approximately HK$1,566.4 million. The Company's public offering in Hong Kong was well received and was over-subscribed, representing approximately 6.2 times the total number of 2,226,800 H shares available for subscription. The portion of the International Offering was also over-subscribed, representing approximately 2.9 times the 20,040,400 H Shares initially available for subscription in the International Offering.

As the company's financial public relations consultant team, Porda Havas participated in the maintenance of domestic and foreign media relations during the company's listing process, strived for positive reports for the company, and conveyed positive messages to the market. At the same time, he also assisted the company in preparing publicity materials for listing, holding listing celebration activities, etc., to help the company successfully list in Hong Kong.

Mr. Zhang Dalei, founder, executive director, chairman and chief executive officer of Airdoc Technology, said: "We are very pleased that the company will be listed on the Hong Kong Stock Exchange soon. This is an important milestone and a new beginning for the development of Airdoc Technology. We also We are very grateful to all investors for their support on the company's growth path. Facing the huge and fast-growing artificial intelligence retinal image recognition market, we look forward to taking this listing as an opportunity to further unleash our growth in medical institutions and various big health scenarios Potential and competitive advantage. We strive to make high-quality healthcare accessible and affordable to everyone, while continuing to create greater value for our shareholders and investors.”

About Beijing Airdoc Technology Development Co., Ltd.

Established in 2015, Beijing Airdoc Technology Development Co., Ltd. ("Airdoc Technology" or the "Company") is one of the first companies in China to provide early detection, diagnosis and health risk assessment solutions for artificial intelligence retinal image recognition. Eagle Eye's solutions use retinal images, multi-modal data analysis and artificial intelligence deep learning algorithms to achieve non-invasive, accurate, fast, effective and scalable detection and diagnosis of chronic diseases in medical institutions and large health scenarios. The company develops three versions of Airdoc-AIFUNDUS as its core product. The company's artificial intelligence medical device software ("SaMD"), Airdoc-AIFUNDUS (1.0), has been approved to assist in the diagnosis of diabetic retinopathy.Airdoc Technology is also developing Airdoc-AIFUNDUS (2.0) and (3.0) to cover more indications. In addition, the company has a product pipeline that includes seven other self-developed SaMD and health risk assessment solutions. At the same time, Airdoc Technology also has three self-developed fundus cameras, which have obtained or are expected to obtain the second-class medical device certificate. These devices are compatible with the company's auxiliary diagnosis SaMD and health risk assessment solutions, which help the company to provide software and hardware. Combined all-in-one healthcare solution. The company has 152 patents and patent applications, and 6 published PCT applications, of which 22 patents and patent applications and 2 published PCT applications are related to its core products.

Latest Update:
5 th November, 2021